PRÉNUMBRA

WIPO WIPO 2020

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark PRÉNUMBRA was filed as Word mark on 08/11/2020 at the World Intellectual Property Organization.

Trademark Details Last update: May 26, 2023

Trademark form Word mark
File reference 1555226
Register number 018202301
Countries Australia Canada Switzerland China Israel South Korea New Zealand Singapore United States of America (USA)
Base trademark EU No. 018202301, June 27, 2020
Application date August 11, 2020
Expiration date August 11, 2030

Trademark owner

Devonshire House, 60 Goswell Road
London EC1M 7AD
GB

Trademark representatives

Thierschstr. 11 80538 München DE

goods and services

05 Pharmaceuticals; pharmaceutical drugs; pharmaceutical preparations; pharmaceuticals used for cerebrovascular accidents (strokes); cardiovascular preparations; cardiovascular pharmaceuticals; cardiovascular pharmaceutical preparations; cardiovascular agents for medical purposes; cardiovascular drugs used in treating shocks; cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; pharmaceutical preparations for the treatment of cardiovascular disease; cardiovascular drugs used in treating congestive heart failure (CHF); pharmaceutical preparations, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; sun tanning preparations for pharmaceutical purposes, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; dermatological preparations; dermatological pharmaceutical substances; dermatological pharmaceutical products; medicinal creams for the protection of the skin; skin care creams for medical use; skin care preparations for medical use; medicated skin creams and lotions; medicated creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; chemical and biological preparations, substances, reagents and compounds for the delivery and storage of pharmaceuticals which are preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; afamelanotide aqueous and gel formulations

Trademark history

Date Document number Area Entry
May 17, 2023 2023/21 Gaz CA RAW: Rule 18ter(2)(ii) GP following a provisional refusal
May 17, 2023 2023/21 Gaz CN RAW: Rule 18ter(4) all goods and services protected
June 7, 2022 2022/23 Gaz KR RAW: Rule 18ter(2)(ii) GP following a provisional refusal
March 24, 2022 2022/13 Gaz US RAW: Rule 18ter(2)(ii) GP following a provisional refusal
January 31, 2022 2022/6 Gaz CA Rejection
November 7, 2021 2021/45 Gaz KR Rejection
September 14, 2021 2021/37 Gaz CH Rejection
September 2, 2021 2021/40 Gaz IL RAW: Rule 18ter(2)(ii) GP following a provisional refusal
May 27, 2021 2021/21 Gaz NZ Rejection
March 31, 2021 2021/13 Gaz SG Rejection
March 22, 2021 2021/17 Gaz RAW: Limitation
February 23, 2021 2021/9 Gaz CN Rejection
January 26, 2021 2021/4 Gaz AU Rejection
January 10, 2021 2021/3 Gaz IL Rejection
December 21, 2020 2020/52 Gaz US Rejection
August 11, 2020 2020/40 Gaz EM Registration

ID: 141555226